Commentary|Articles|November 18, 2026

NeuroVoices: Brian Lin, PhD, on the FDA Approval of Gefurulimab for Generalized Myasthenia Gravis

Listen
0:00 / 0:00

The senior director of research at the Muscular Dystrophy Association discussed what the newly approved once-weekly C5 inhibitor adds to generalized myasthenia gravis care.

Recently, the FDA approved gefurulimab (Klygefa; Alexion and AstraZeneca), a once-weekly, self-administered subcutaneous complement C5 inhibitor, for adults with antiacetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG).1,2 A dual-binding nanobody, gefurulimab binds C5 in the terminal complement cascade and also binds serum albumin, which extends its half-life and allows weekly dosing by autoinjector after a weight-based loading dose on day 1.

The approval was supported by the phase 3 PREVAIL trial (NCT05556096), in which 260 adults with AChR-Ab+ gMG were randomly assigned to gefurulimab (n = 131) or placebo (n = 129) for 26 weeks.3 At week 26, least-squares mean change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score was –4.2 with gefurulimab vs –2.6 with placebo (treatment difference, –1.6; 95% CI, –2.4 to –0.8; P <.001), and change in Quantitative Myasthenia Gravis (QMG) total score was –4.5 vs –2.4 (treatment difference, –2.1; 95% CI, –3.1 to –1.1; P <.001), with improvements seen within 1 week on MG-ADL and 4 weeks on QMG.

Following the approval, the Muscular Dystrophy Association (MDA), which has invested more than $57 million in MG research, publicly welcomed the new option.2 Brian Lin, PhD, senior director of research at MDA, offered his perspective on what the therapy means for patients and clinicians. In a new iteration of NeuroVoices, Lin discussed what a once-weekly, at-home complement inhibitor offers patients and clinicians, as well as the evidence behind gefurulimab. He also shared how personalized treatment in gMG has evolved, the open questions clinicians face as the drug enters practice, and where research should focus next.

NeurologyLive: What does the approval of gefurulimab bring to the gMG community, and what advantages and flexibility does another option provide for physicians and patients?

Brian Lin, PhD: Gefurulimab adds another option within the complement inhibitor class, with a potentially meaningful difference in how treatment is delivered. It is designed as a once-weekly, self-administered subcutaneous injection, offering an alternative to treatments that require more frequent injections or infusions at a care center. For comparison, for adults, eculizumab is typically administered every 2 weeks, ravulizumab every 8 weeks, and zilucoplan daily. A weekly at-home option could offer a middle ground in terms of treatment frequency and convenience.

These practical differences matter for people managing a chronic condition. Treatment schedules, travel to infusion centers, and time away from work can all influence a patient’s experience. It also gives physicians greater flexibility to consider treatment options based on disease characteristics, prior treatment response, and individual preferences. Ultimately, having another option within an established therapeutic class may help more patients find a treatment approach that fits their needs and lifestyle.

What evidence supports the efficacy and safety of gefurulimab in gMG?

The evidence supporting gefurulimab builds on an established therapeutic approach. In most patients with AChR-antibody–positive gMG, antibodies activate the complement system at the neuromuscular junction, contributing to damage that impairs muscle function. Blocking C5 interrupts this process, a mechanism already validated by other treatments such as eculizumab, ravulizumab, and zilucoplan. Gefurulimab uses a dual-binding nanobody that targets C5 and binds albumin, extending its half-life and allowing for once-weekly subcutaneous administration.

The pivotal phase 3 PREVAIL trial evaluated gefurulimab in 260 adults with AChR-antibody–positive gMG over 26 weeks. Patients receiving gefurulimab demonstrated greater improvements in both MG-ADL and QMG scores compared with placebo, with improvements in daily functioning observed as early as the first week. The safety profile was generally comparable to placebo, although infection risks associated with complement inhibition remain important considerations. Overall, these results provide encouraging evidence of efficacy, while longer-term studies will help further characterize its safety and durability of benefit.

How has the ability to personalize treatment choices for patients with gMG evolved over the years?

Historically, gMG treatment relied largely on symptomatic therapies and broad immunosuppression, including corticosteroids and other immunosuppressive medications. While these treatments have helped many patients, they can take time to work and carry significant long-term treatment burdens.

Our understanding of the underlying immunology has changed how we approach treatment. Identifying different antibody subtypes, particularly AChR and MuSK antibodies, has helped demonstrate that MG is not a single, uniform disease. For example, AChR-positive MG can involve complement activation, making complement inhibitors a rational treatment approach, whereas MuSK-positive disease has a different underlying mechanism and may respond better to other targeted approaches.

Today, we have several targeted therapeutic classes, including complement inhibitors, FcRn antagonists, and B-cell–directed therapies. The remaining challenge is determining which treatment will work best for each individual. Antibody status helps guide decisions, but we still lack reliable biomarkers to predict treatment response.

What questions will the clinical community need to answer regarding how gefurulimab is used and prescribed?

Given its approval, one of the first questions will be where gefurulimab fits within the existing treatment landscape. Will it be used earlier in treatment, or primarily in patients who have not responded adequately to other therapies? And when a patient does not respond to one C5 inhibitor, is switching to another within the same class worthwhile, or would changing to a different therapeutic mechanism be more appropriate? Without head-to-head trials, these decisions will initially rely on clinical experience and emerging real-world evidence.

We will also need to better understand which patients are most likely to benefit. PREVAIL studied adults with AChR-antibody–positive generalized MG, so additional evidence will be needed to understand its role in broader patient populations. Longer-term questions include whether treatment can help reduce corticosteroid use, how best to manage infection risks associated with complement inhibition, and how patients do with sustained treatment. Finally, practical considerations such as affordability, insurance coverage, and support for self-administration will influence how accessible this option is in clinical practice.

With so many emerging treatment options, what should the clinical community focus on from a research standpoint over the coming years?

I think the field is at an interesting point. Ten years ago, one of our biggest challenges was the lack of targeted treatment options. Today, we have a growing number of therapies, but we still have relatively little guidance on how to select the right treatment for the right patient. Comparative effectiveness studies, treatment-sequencing research, and better biomarkers to predict treatment response should be major priorities. We also need to better distinguish ongoing autoimmune disease activity from residual damage, since not all persistent symptoms will necessarily improve with additional immunotherapy.

At the same time, we should continue raising our expectations for treatment outcomes. The goal should extend beyond symptom improvement toward sustained disease control, reduced treatment burden, and ideally steroid-free remission. There is exciting research emerging around more durable approaches to treating MG, including plasma-cell-directed therapies and investigational cellular therapies such as CAR T. Ultimately, the next phase of research should focus not just on developing more treatments, but on understanding how to use them most effectively to improve long-term outcomes for patients.

Transcript edited for clarity. Click here to view more NeuroVoices.

REFERENCES
1. KLYGEFA (gefurulimab-gaks) approved in the US for the treatment of generalized myasthenia gravis (gMG) in adult patients. News release. AstraZeneca. November 16, 2026. Accessed November 17, 2026. https://www.astrazeneca-us.com/media/press-releases/2026/KLYGEFA-gefurulimab-gaks-approved-in-the-US-for-the-treatment-of-generalized-myasthenia-gravis-gMG-in-adult-patients.html
2. FDA approves KLYGEFA, expanding treatment options for generalized myasthenia gravis. News release. Muscular Dystrophy Association. November 16, 2026. Accessed November 17, 2026. https://www.mda.org/press-releases/fda-approves-klygefa-expanding-treatment-options-for-generalized-myasthenia-gravis
3. Gwathmey KG, Saccà F, Howard JF Jr, et al. Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. JAMA Neurol. 2026;83(9):841-850. doi:10.1001/jamaneurol.2026.2333

Related to this article